TKTakanobu Kojimahara

Takanobu Kojimahara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takanobu Kojimahara has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Hideki Mizunuma

    Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine

    2 shared publications
  • Hirohisa Kurachi

    Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine

    2 shared publications
  • Kenji Nakahara

    Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine

    2 shared publications
  • Nobuo Yaegashi

    Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine

    2 shared publications
  • Tadahiro Shoji

    Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine

    2 shared publications
  • Tadao Takano

    Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine

    2 shared publications

Latest Publications

  • Open Access

    Yolk Sac Tumor of the Ovary: A Retrospective Multicenter Study of 33 Japanese Women by Tohoku Gynecologic Cancer Unit (TGCU)

    by Takanobu Kojimahara, Kenji Nakahara, Tadao Takano, Nobuo Yaegashi, Hiroshi Nishiyama, Keiya Fujimori, Naoki Sato, Yukihiro Terada, Toru Tase, Yoshihito Yokoyama, et al.

    Yolk sac tumor (YST) of the ovary is a rare germ cell tumor comprising about 1% of all ovarian malignancies. YST usually occurs as a rapidly growing unilateral tumor in young women. With the introduction of cisplatin, YST has been changed from a fatal tumor to a curable tumor. The standard treatment of YST consists of fertility-preserving surgery and 3 or 4 courses of adjuvant combination chemotherapy with bleomycin, etoposide, and cisplatin (BEP). However, the long-term prognosis of BEP-treated YST patients has not been well studied. We therefore conducted a retrospective multicenter study to investigate the prognostic factors of 33 YST patients, including 25 patients treated with BEP. The median age at initial treatment was 20 years (range 10-53). There were 15 patients (at stage I), one (stage II), 16 (stage III), and one (stage IV). Nominal and grouped numerical values were analyzed by the Kaplan-Meier method. All patients had unilateral tumor, with right-side predominance (23 patients; P = 0.02). Eighteen patients had pure YST, 13 had mixed germ cell tumor with YST component, and other 2 patients were not specified. Twenty-eight patients received fertility-preserving surgery. Twenty-seven patients had optimal surgery with less than 1 cm residual tumor diameter. Median number of chemotherapy courses was 5. Median follow-up period was 49 months. The cumulative 5-year survival rate was 87%. Univariate analysis revealed the following significant prognostic factors (P < 0.05): stage, tumor diameter, and residual tumor. Extensive debulking surgery to minimize residual tumor would improve the prognosis.


  • Open Access

    Identifying Prognostic Factors in Japanese Women with Pseudomyxoma Peritonei: A Retrospective Clinico-Pathological Study of the Tohoku Gynecologic Cancer Unit

    by Takanobu Kojimahara, Kenji Nakahara, Tadahiro Shoji, Toru Sugiyama, Tadao Takano, Nobuo Yaegashi, Yoshihito Yokoyama, Hideki Mizunuma, Ryo Tase, Hirokazu Satou, et al.

    Pseudomyxoma peritonei (PMP) is a rare condition of mucinous ascites associated mainly with mucinous tumors of appendix or ovary. PMP often recurs after treatment and may eventually cause death by abdominal visceral dysfunction via compression with mucinous ascites. Although radical peritonectomy and hyperthermic intra-peritoneal chemotherapy are becoming popular globally, the optimal treatment of PMP has not been established in Japan. We conducted a retrospective multicenter study to clarify the optimal treatment and the prognostic factors of PMP. A total of 23 patients with PMP were analyzed in the Tohoku Gynecologic Cancer Unit (TGCU). Clinical and follow-up data were retrieved and a central pathology review was performed. The median follow-up period was 46 months. Eleven patients underwent complete resection. There were 7 deaths out of 13 recurrences/progressions in this period. All the recurrence/progression was confined to the abdomen. Unexpectedly, neither radical peritonectomy nor hyperthermic intra-peritoneal chemotherapy had been performed, indicating that both radical peritonectomy and hyperthermic intra-peritoneal chemotherapy are not yet popular in Japan. The medians of overall survival and disease-free period were 166 months and 30 months, respectively. Univariate and multivariate analyses revealed that the only prognostic factor was macroscopic residual tumor (P = 0.022). Although chemotherapy was not a prognostic factor (P = 0.16), those who received intra-peritoneal chemotherapy tended to have a better prognosis than those who received systemic or no chemotherapy (P = 0.064). In conclusion, the macroscopic residual tumor is an important prognostic factor in Japanese patients with PMP.